Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
US-9487535-B2 · Nov 8, 2016 · US
Isatin spiro compounds with antibacterial activities and a method of preparing the same
US10072020B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-10072020-B1 |
| Application number | US-201815957867-A |
| Country | US |
| Kind code | B1 |
| Filing date | Apr 19, 2018 |
| Priority date | Apr 3, 2018 |
| Publication date | Sep 11, 2018 |
| Grant date | Sep 11, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An isatin spiro compound having the following formula (I): R 1 is halogen or C 1-3 alkyl; R 2 is C 1-3 alkyl or benzyl; and R 3 and R 3′ are independently H, C 1-3 alkyl or phenyl.
First claim
Opening claim text (preview).
What is claimed is: 1. An isatin spiro compound having the following formula (I): wherein R 1 is halogen or C 1-3 alkyl; R 2 is C 1-3 alkyl or benzyl; and R 3 and R 3′ are independently H, C 1-3 alkyl or phenyl. 2. The isatin spiro compound of claim 1 , wherein R 1 is Cl or Br. 3. The isatin spiro compound of claim 1 , wherein R 2 is methyl, ethyl, propyl, or benzyl. 4. The isatin spiro compound of claim 1 , wherein R 3 and R 3′ are independently H or phenyl. 5. The isatin spiro compound of claim 1 , wherein the compound is selected form the group consisting of: 6. A method of preparing the isatin spiro compound of claim 1 comprising: reacting a compound of formula (II) with a compound of formula (III) and a compound of formula (IV) in a one pot reaction, wherein R 1 is halogen or C 1-3 alkyl; R 2 is C 1-3 alkyl or benzyl; and R 3 and R 3′ are independently H, C 1-3 alkyl or phenyl; wherein the non-polar solvent is selected from the group consisting of benzene, CCl 4 , toluene, and THF; and wherein the catalyst includes a strong acid cation exchange resin, ferrocene, and palladium acetate. 7. The method of the claim 6 , wherein a molar ratio of the compound of formula (II) to the compound of formula (III) is 1:1 to 1:1.5. 8. The method of the claim 6 , wherein a molar ratio of the compound of formula (II) to the compound of formula (IV) is 1:1 to 1:1.2. 9. The method of claim 6 , wherein the strong acid cation exchange resin includes a 7% crosslinked styrene divinylene copolymer with sulfonic acid group (—SO 3 H).
Assignees
Inventors
Classifications
Antibacterial agents · CPC title
- C07D491/107Primary
with only one oxygen atom as ring hetero atom in the oxygen-containing ring · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10072020B1 cover?
- An isatin spiro compound having the following formula (I): R 1 is halogen or C 1-3 alkyl; R 2 is C 1-3 alkyl or benzyl; and R 3 and R 3′ are independently H, C 1-3 alkyl or phenyl.
- Who is the assignee on this patent?
- Liang Chengyuan, Tian Danni, Ding Shunjun, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07D491/107. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).